The Canceropôle Provence-Alpes-Côte d'Azur and SATT Sud-Est are proud and happy to announce the renewal of their partnership for a period of two years.
Clara DUCORD, Director of the Canceropôle Provence-Alpes-Côte d'Azur, and Laurent BALY, President of SATT Sud-Est, sign the renewal of the partnership between the two entities at the headquarters of SATT Sud-Est in Marseille.
Clara DUCORD, Director of the Canceropôle Provence-Alpes-Côte d'Azur, and Laurent BALY, President of SATT Sud-Est, have signed the renewal of the partnership between the Canceropôle and SATT Sud-Est, whose objectives are:
- Maximize the investments of SATT Sud-Est and Canceropôle in technological and economic development,
- Encourage the co-financing of one to two projects each year in oncology,
- Accelerate their transfers to the industrial world,
- Organize events to better identify the anti-cancer innovations developed by researchers in the Region.
During the first agreed collaboration period, between September 2018 and September 2020,7 projects were supported and co-financed. These are ledby the research teams ofStéphane ROCCHI (C3M, Nice) & Rachid BENHIDA (ICN, Nice) , Xavier MORELLI (CRCM, Marseille) & Patrice DUBREUIL (CRCM, Marseille) ,Hervé RIGNEAULT (Institut Fresnel, Marseille), François DEVRED (INP, Marseille) , Valérie VOURET-CRAVIARI(IRCAN, Nice), Mohamed MEHIRI (ICN, Nice) and Thierry PASSERON (C3M, Nice) & Rachid BENHIDA (ICN, Nice).
Recently, 3 new projects, winners of the " Premature " call for projects,have entered the field of this partnership. These 3 anti-cancertechnologies will benefit from funding from the Canceropôle and support from SATT Sud-Est. The projects are led by Fabienne BRENET (CRCM, Marseille), Flavio MAINA (IBDM, Marseille) and Jérémie ROUX (IRCAN, Nice).
From ls excellence in research.is looking for territorial and this partnership, the biotech niçoise Yukin TherapeuticsShe is a graduate of 2 patents co-owned by the University of the Côte d'Azur, Inserm, CNRS and the Nice University Hospital.raised €3.3 million in funds and has seen the South-East SATT enterss capital. The start-up is developing ahe strategy Therapeutic targeting skin cancer, as well as most solid cancers including pancreatic cancer.. These beautifuls successs spouses and more to come strengthen the role of of the Canceropole Provence-Alpes-Côte d'Azur and SATT Southeast in the attractiveness of the region and the establishment of young innovative companies.
- Consult the news on the Canceropôle website
- Watch our video "CRO15, a novel chemical compound for targeted cancer treatment".
@SATTse_ @CanceropolePACA @NetworkSATT #cancer #oncology